Tirzepatide effectively reduced albuminuria in patients with type 2 diabetes mellitus without worsening renal function. The effect of the drug was significant even at baseline urinary albumin/creatinine ratio of 30 mg/g and higher.
About it tells the online resource "Nachmed".
Researchers from the Aristotelian University of Thessaloniki found that the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide showed high efficacy in reducing albuminuria levels in patients with type 2 diabetes. The results of the study were published in the journal Diabetes, Obesity and Metabolism.
Tirzepatide reduced the urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus by approximately 27%. This effect was maintained at all doses of tirzepatide. Against the background of taking 5 mg of the drug albuminuria decreased by 23,12%. When taking 10 mg of tirzepatide, the ratio of albumin to creatinine in urine decreased by 27.87%, and at 15 mg - by 27.15%.
Patients with high levels of albuminuria before the start of the study (30 mg/g or more) had a 41.42% reduction.
The effect of tirzepatide was significantly superior to placebo and comparable to semaglutide. At the same time the calculated rate of glomerular filtration practically did not change.
| Data from 6226 patients receiving tirzepatide (5 mg, 10 mg, or 15 mg) and 3307 control participants who were taking placebo, semaglutide, or insulin were analyzed. |
Researchers believe that tirzepatide may be a drug that can prevent and slow the development of chronic kidney disease and related replacement therapy in patients with type 2 diabetes.
You will also be interested in the material titled "The head of the laboratory of the clinical and diagnostic center in Bryansk has been arrested in a bribery case".
